PATENTVEST PULSE REPORT
Beyond GLP-1: The Crossover
How FGF21 Is Becoming the Cardiometabolic Layer Beneath GLP-1
The next obesity opportunity may not come from a better GLP-1 drug.
As major pharmaceutical companies invest more than $10.7 billion in FGF21 platforms, the market is shifting beyond weight loss toward therapies designed to address the metabolic conditions GLP-1 leaves behind.
PatentVest's latest Pulse analyzes the companies, partnerships, clinical programs, and intellectual property shaping this emerging competitive landscape.
Request access to the full analysis.
Key Takeaways
- Why FGF21 is emerging as the next strategic layer beyond GLP-1.
- How Novo Nordisk, Roche, GSK, Eli Lilly, AstraZeneca, and other industry leaders are positioning themselves.
- The partnerships, acquisitions, and IP trends reshaping the next phase of obesity therapeutics.
- Why competitive advantage may increasingly depend on platform strategy and intellectual property—not weight-loss efficacy alone.